Kazunori Uenaka

Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors

Maki Tanioka, Hiroshi Nokihara, Noboru Yamamoto et al. · Cancer Chemotherapy and Pharmacology · 2010 · 83 citations

Medicine, Molecular Biology, Oncology +9

Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Mellitus

Prajakti A. Kothare, Helle Linnebjerg, Yoshitaka Isaka et al. · The Journal of Clinical Pharmacology · 2008 · 63 citations

Medicine, Pharmacokinetics, Pharmacology +8

Comparison of Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of the Amyloid β Monoclonal Antibody Solanezumab in Japanese and White Patients With Mild to Moderate Alzheimer Disease

Kazunori Uenaka, Masako Nakano, Brian A. Willis et al. · Clinical Neuropharmacology · 2011 · 42 citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Phase I study of LY2603618, a CHK1 inhibitor, in combination with gemcitabine in Japanese patients with solid tumors

Toshihiko Doi, Takayuki Yoshino, Kohei Shitara et al. · Anti-Cancer Drugs · 2015 · 32 citations

Medicine, Oncology, Pharmacology +16

A non-randomized, open-label, single-arm, Phase 2 study of emibetuzumab in Asian patients with MET diagnostic positive, advanced gastric cancer

Daisuke Sakai, Hyun Cheol Chung, Do‐Youn Oh et al. · Cancer Chemotherapy and Pharmacology · 2017 · 31 citations · Full text

Medicine, Oncology, Pharmacology +17